

PERSONALIA

Robrecht Pieters

Born: 17 December 1959, Utrecht.

BIG-number: 69023258301

**WORK**

Chief Medical Officer, Board of Directors
Princess Máxima Center for Pediatric Oncology
Heidelberglaan 25
3584 CS Utrecht

T: +31 6 5524 0314 (assistant Mrs. Jacqueline Dito)

E: r.pieters@prinsesmaximacentrum.nl

POSITIONS

- 1978-1987: Faculty Human Movement Studies, Free University, Amsterdam
- 1979-1987: Faculty of Medicine, Free University, Amsterdam
- 1987-1991: PhD, research laboratory of Pediatric Oncology, Free University, Amsterdam (Dutch Cancer Society 87-17). PhD degree March 1991. Thesis: "Drug resistance in childhood leukemia (promotor prof dr AJP Veerman)
- 1991-1995: Training Pediatrics, Free University, Amsterdam
- 1995-1998: Pediatrician, division of pediatric oncology/hematology/immunology, Free University Amsterdam
- 1996-1998: Clinical fellowship Dutch Cancer Society
Departments of hematology Free University Hospital Amsterdam (prof Huygens),
pediatric bone marrow transplantation Leiden University Medical Center (prof Vossen),
pediatric oncology/hematology/immunology, Free University Amsterdam (prof Veerman),
pediatric oncology Academic Medical Center Amsterdam (prof Voute)
- 1996-1999: Associate professor pediatric oncology/hematology (UHD), Free University Amsterdam
- 1999-2014: Head department of pediatric oncology/hematology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam
- 2000-2017: Professor Pediatric Oncology, Erasmus University, Rotterdam
- 2011-2013: Project director Princess Máxima Center for Pediatric Oncology
- 2013-present: Chief Medical Officer, co-CEO, Board of Directors, Princess Máxima Center for Pediatric Oncology
- 2016-present Professor Pediatric Oncology, Utrecht University

PUBLICATIONS

See separate file.

PRESENTATIONS

See separate file.

AWARDS

- 1991 Young Investigators Award (2nd) of the Dutch Pediatric Association
- 1991 Kabi Pharmacia Research Award
- 1992 Schweisguth Prize of the International Society of Paediatric Oncology
- 2014 ODAS award
- 2018 Royal knighthood decoration as Officer in the Order of Oranje Nassau

NATIONAL BOARDS/COMMITTEES/ADVISORY BOARDS

- Chairman of the ALL disease committee of the Princess Máxima Center, 2018-present
- Member Supervisory Board Ronald McDonald Childhood Foundation, 2017-2023
- Member Board Kiem Foundation, 2021-2023
- Member board Princess Máxima Center Foundation, 2017-2022
- Chairman ALL disease committee of the Dutch Childhood Oncology Group (DCOG), 2002-2018
- Chairman DCOG ALL-11 protocol, 2010-2018
- Chairman DCOG infant ALL committee, 1996-2018
- Chairman DCOG Ph+ ALL committee, 1999-2018
- Chairman board Foundation Support Princess Máxima Center, 2013-2016
- Member of “Oncologisch Beraad”, Erasmus MC Rotterdam, 1999-2014.
- Member Internal Scientific Board of the Erasmus Stem Cell Institute, 2009- 2011
- Member faculty MSc Molecular Medicine programme Erasmus MC, 2005-2014
- Member Scientific Board Dutch Cancer Society (KWF), 2012-2018
- Chairman Supervisory Board Dutch Childhood Oncology Group, 2008-2014
- Member Dutch Health Council committee “Origin of Childhood Leukemia”, 2010-2012
- Chairman of the Working Group Pediatric Oncology of the Integraal Kanker Centrum Rotterdam (IKR), 2002-2007.
- Member of “Commissie Bevordering Wetenschappelijk Personeel” Erasmus MC, 2007-2010
- Chairman of “Beraadsgroep Voortplantingsgeneeskunde” ErasmusMC, 2006-2009
- Member Committee Project Topkwaliteit Klinische Trials (TKT) Erasmus MC, 2006-2008
- Member Steering Committee Kenniscentrum Palliatieve Zorg Erasmus MC, 2005-2008
- Chairman Pediatric Research Committee Erasmus MC-Sophia, 1999-2008
- Secretary Dutch Childhood Oncology Group (DCOG), 2002-2007
- Board Member Dutch Childhood Leukemia Study Group, 1999-2002
- Member Research Committee DCLSG/DCOG, 1997-2006
- Chairman DCOG ALL-10 protocol, 2004-2012
- Member committee ANLL-94, Dutch Childhood Leukemia Study Group (DCLSG), 1995-1996
- Projectleader theme Hematologic Malignancies, Oncology Research School Free University, 1996-1998

INTERNATIONAL BOARDS/COMMITTEES/ADVISORY BOARDS

- Advisory Board I-BFM, 2023- present
- Advisor Daruieste Viata Foundation, Bucharest, 2023-present
- Board Member European Union Cancer Mission Board, 2022-present
- Member External Advisory Board, Hospital Sant Joan de Déu and the Pediatric Cancer Center Barcelona, 2022-present
- Board Member Translational Research and Innovation Programme (TRIP), IRB Barcelona, 2022-present
- Board Member of the European Society of Pediatric Oncology (SIOPE), 2022-present
- Member SIOP Scientific Programme Advisory Committee (SPAC), 2021-present
- Member Advisory Committee VAGABOND, 2020-present
- Member Scientific Advisory Board iCope and CONTROL’s Advisory Board, Copenhagen, Denmark, 2020-present
- Member Scientific Advisory Board St Jude Children’s Research Hospital, Memphis, USA, 2020-present
- council member Gerson Lehrman Group Health Care & Biomedical Council, 2017-present
- Chair Interfant group, international study group for treatment of infants with ALL, chair Interfant-99 protocol, Interfant-06 protocol, 1999-present
- Member EsPhALL study committee, international treatment protocol for children with Ph+ ALL, 1999-present

- Member ALLTogether protocol, international treatment protocol for children with ALL, 2017-present
- Advisory Board member of I-BFM, international consortium for children with hematologic malignancies, 2008-present
- Member of Ponte di Legno Group, international consortium for diagnostic and treatment guidelines for childhood ALL, 1999-present
- Member of Acute Lymphoblastic Leukemia Strategy Committee, International BFM Study Group, 1996-present
- Member of Biology and Diagnosis Committee International BFM Study Group, 1996-present
- Member of the Scientific Advisory Board of the Consortium on Individualized therapy for Relapsed Malignancies in Childhood (INFORM) of the German Gemeinschaft für Pädiatrische Onkologie und Hämatologie (GPOH), 2013-present
- Member Scientific Advisory Board for Center for Precision Medicine in Leukemia, SJCRH, Memphis, USA, 2015 – 2017
- Member Scientific Evaluation Committee Early Phase Clinical Trial Centres, Institute National du Cancer (INCa), France, 2015-2019
- Member Cancer Research UK Science Committee/Discovery Research Committee, 2018-present
- Member Cancer Research UK Expert Review Panel, 2017-present
- Board member of the International Society of Pediatric Oncology (SIOP), 2010-2012
- Scientific Advisor of the German Kompetenznetz Pädiatrische Onkologie, 1999-2005
- Member Scientific Committee International Society of Pediatric Oncology (SIOP), 2004-2009
- Chair Scientific Committee International Society of Pediatric Oncology (SIOP) 2010-2013
- Member Biology and Preclinical Evaluation Committee Innovative Therapies for Children with Cancer (ITCC), 2004
- Member European Hematology Association (EHA) Selection Committee EHA Fellowship Program 2010
- Member European Hematology Association (EHA) Scientific Program Advisory Committee, 2005-2009
- Member of the Children's Cancer and Leukaemia Group Scientific Steering Committee of Cancer Research UK, 2007-2011
- Member Scientific Committee on Blood Disorders in Childhood, American Society of Hematology, 2009-2010
- Chair Scientific Committee on Blood Disorders in Childhood, American Society of Hematology, 2011-2012

INTERNATIONAL DATA SAFETY MONITORING BOARDS (DSMB)

- Chairman DSMB Dana Farber Cancer Institute ALL trials, USA, 2008-present
- Chairman DSMB HOVON/EORTC-ALL 100 study, Europe, 2009-2017
- Member DSMB COALL Study 08-09, Germany, 2010-2022
- Member DSMB GMALL 08/2013, 2013-present
- Chairman DSMB UKALL2011 Study, UK, 2011-2023
- Member DSMB Asparec (Jazz Pharmaceuticals), USA, 2015- present
- Member DSMB GMALL recombinant pegylated asparaginase study (Pegasp.1/Adults), Germany, 2010-2014

MEMBERSHIP OF ASSOCIATIONS

- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
- Dutch Childhood Oncology Group (DCOG)
- Dutch Hematology Association (NVvH)
- Dutch Oncology Association (NVvO)

- Dutch Pediatric Association (NVK)
- European Hematology Association (EHA)
- International Society of Paediatric Oncology (SIOP)
- European Society for Pediatric Oncology (SIOP Europe)

EDITORIAL BOARD

- Editor in chief European Journal of Cancer Pediatric Oncology, 2022-present
- Editor pediatric section of European Journal of Cancer, 2010-2022
- Editorial Board Haematologica, 2008-present
- Editorial Board Advances in Cell and Gene Therapy, 2017-2020
- Editorial Board Pediatric Blood and Cancer, 2004-2009, 2014-2017
- Editor Cochrane Childhood Cancer Review Group, 2005-present
- Editorial board European Oncology & Haematology, 2010-2013
- Editorial Advisory panel US Hematology, 2009-2013
- Editorial Board member European Journal of Clinical & Medical Oncology, 2009-2013
- Editorial Board member Kinderarts en Wetenschap, 2012-2015
- Section head Pediatric Oncology, F1000prime, 2013-2017
- Associate editor Pediatric Blood and Cancer, 2009-2014
- Editorial Board Member, Investigational New Drugs, the journal of new anticancer agents, 1997-1999
- Board member Pediatric Clinics of Amsterdam 1994-1995

REVIEWER

- Peer Reviewer for the following journals:
 - Annals of Oncology
 - Annals of Hematology
 - Biochemical Journal
 - Blood
 - British Journal of Cancer
 - British Journal of Haematology
 - Cancer Chemotherapy Pharmacology
 - Cancer Research
 - Clinical Cancer Research
 - European Journal of Cancer
 - European Journal of Haematology
 - Haematologica
 - International Journal of Cancer
 - International Journal of Radiation Biology
 - Journal of Biomedicine and Biotechnology
 - Journal of Clinical Oncology
 - Journal of Immunological Methods
 - Journal of Pediatric Hematology Oncology
 - Journal of Pediatric Surgery
 - Lancet
 - Lancet Child & Adolescent Health
 - Lancet Oncology
 - Leukemia
 - Leukemia Research
 - Leukemia Lymphoma
 - Nature Communications
 - Nature Genetics

- Nature Medicine
- Nature Protocols
- New England Journal of Medicine
- Pediatric Blood and Cancer
- Pharmacogenetics
- Review for the following cancer organisations:
 - Agency for Science, Technology and Research's Biomedical Research Council, Singapore
 - Austrian Science Fund (FWF)
 - Autonomous Province of Bolzano-South Tyrol
 - Belgian Foundation against Cancer, Belgium
 - Bloodwise, UK
 - Cancer Research UK
 - Discovery Research Committee
 - Expert Review Panels
 - Clinical Research Monitoring Panel - Stratified Medicine Paediatrics Programme
 - Cancer Therapy Evaluation Program (CTEP), National Cancer Institute USA
 - Childhood Oncology Group (COG), USA
 - Deutsche Forschungsgemeinschaft (DFG), Germany
 - Dutch Cancer Society
 - French NCI Scientific Evaluation Committee
 - German Kompetenz Network Pediatric Oncology
 - Great Ormond Street Hospital Children's Charity
 - Kay Kendall Leukaemia Fund, United Kingdom
 - Leukemia & Lymphoma Research, United Kingdom
 - Leukemia Research Fund, United Kingdom
 - National Cancer Institute's Cancer Therapy Evaluation Program, USA
 - Netherlands Organisation for Health Research and Development (NWO)
 - Pediatric Cancer Center Barcelona – Sant Joan de Deu Children's Hospital
 - Portuguese ministry for science and technology (FCT Portugal)
 - Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek - Vlaanderen, FWO)
 - Swiss Cancer League
 - The Academy of Medical Sciences, London, UK
 - United Kingdom Childhood Cancer Study Group
 - Czech Health Research Council
 - José Carreras Leukaemia Foundation (Germany)
- Review of meeting abstracts:
 - American Society of Hematology (ASH)
 - European Haematology Association (EHA)
 - International Society Pediatric Oncology (SIOP)
- Member committees for full professorship appointments:
 - Hematopoietic Stem Cell Transplantation 2005 (Erasmus University Rotterdam)
 - MicroRNA and pathogenesis 2008 (Erasmus University Rotterdam)
 - Molecular leukemogenesis 2009 (Erasmus University Rotterdam)
 - Palliative Oncology Care 2010 (Erasmus University Rotterdam)
 - Childhood Pathology 2010 (Erasmus University Rotterdam)
 - Hematology 2010 (Erasmus University Rotterdam)
 - Pediatric Molecular Hemato-oncology 2013 (Erasmus University Rotterdam)
 - Oncological Neurosurgery in children 2018 (Utrecht University)
 - Pediatric Oncology Supportive Care 2019 (University of Groningen)
 - Survivorship & methods in evidence based pediatric oncology 2019 (Utrecht University)
 - Pathobiology of leukemia 2023 (Utrecht University)

- International Examiner International PhD Thesis
 - Newcastle, England, 1996; Thesis "A study of in vitro drug resistance of leukaemic cells from patients with acute lymphoblastic leukaemia" ZT Maung
 - Stockholm, Sweden, 1996; Thesis "Studies on methotrexate and cladribine; bioanalytical, pharmacokinetic and clinical aspects" F Albertioni
 - Lahore, Pakistan, 2009; Thesis "Characterization of cytogenetic and molecular genetic changes and their prognostic impact in leukaemic patients" M Faiz
 - Copenhagen, Denmark, 2014; Thesis "Prolonged First-line PEG-asparaginase Treatment in Childhood Acute Lymphoblastic Leukemia". L Tram Henriksen
 - Aarhus, Denmark 2021; Thesis "Childhood acute lymphoblastic leukaemia and surveillance regimes". K Schow Jensen
 - Aarhus, Denmark 2023; Thesis "PEG-asparaginase pharmacokinetics and sequelae after venous thromboembolism in patients treated for acute lymphoblastic leukemia" Merete Eybye Dam

PROMOTOR of PhD theses

- Kaspers GJL. Drug resistance in newly diagnosed childhood leukemia. A prospective in vitro study.
(promotor AJP Veerman, co-promotor R Pieters), Amsterdam, 1993
- Klumper E. Drug resistance and relapsed leukemia.
(promotor AJP Veerman, co-promotor R Pieters), Amsterdam, 1995
- Den Boer ML. Anthracycline resistance in childhood leukemia.
(promotor AJP Veerman, co-promotor R Pieters), Amsterdam, 1998
- Rots M. Classification and circumvention of methotrexate resistance in childhood leukemia; a clinically directed laboratory study.
(promotor AJP Veerman, co-promotors G Jansen, GJ Peters, R Pieters), Amsterdam, 2000
- Van den Heuvel-Eibrink MM. Multidrug resistance studies in patients with acute myeloid leukemia.
(promotors P Sonneveld and R Pieters), Rotterdam 2001
- Ramakers-van Woerden NL. Genotype and drug resistance in acute lymphoblastic leukemia.
(promotors AJP Veerman and R Pieters), Amsterdam, 2002
- Zwaan CM. Towards subgroup-directed therapy in acute myeloid leukemia
(promotors AJP Veerman and R Pieters, copromotor GJL Kaspers), Amsterdam, 2003
- Haarman EG. Glucocorticoid resistance in childhood leukemia; mechanisms and modulation.
(promotors AJP Veerman and R Pieters, copromotor GJL Kaspers), Amsterdam, 2004
- Stams WAG. Genetic and biological diversity in TEL-AML1 positive ALL.
(promotor R Pieters, co-promotors ML den Boer, HB Beverloo), Rotterdam 2005
- Holleman A. Novel genomic determinants of apoptotic defects in acute lymphoblastic leukemia.
(promotor R Pieters, co-promotor ML den Boer), Rotterdam 2006
- Tissing WJE. Molecular mechanisms of glucocorticoid resistance in childhood acute lymphoblastic leukemia.
(promotor R Pieters, co-promotors ML den Boer, JPP Meijerink), Rotterdam 2006
- Stam RW. Molecular insights in MLL rearranged acute leukemia.
(promotor R Pieters, co-promotor ML den Boer), Rotterdam 2006
- De Koning BAE. Chemotherapy induced intestinal mucositis; from bench to bed.
(promotor R Pieters, co-promotor S Einerhand), Rotterdam 2008
- Appel IM. Pharmacodynamics of L-asparaginase in childhood acute leukemia.
(promotor R Pieters, co-promotor ML den Boer), Rotterdam 2008
- Van Vlierberghe P. Molecular-genetic insights in pediatric T-cell acute lymphoblastic leukemia.
(promotor R Pieters, co-promotors JPP Meijerink, HB Beverloo), Rotterdam 2008
- Van Grotel M. Identification of prognostic genetic factors in pediatric T-cell acute lymphoblastic leukemia.

- (promotor R Pieters, co-promotores JPP Meijerink, MM van Noesel), Rotterdam 2008
- De Bont JM. Biological markers in pediatric brain tumors.
(promotor R Pieters, co-promotor ML den Boer), Rotterdam 2008
- Hartman JM. Motor performance following chemotherapy for childhood cancer.
(promotor R Pieters), Rotterdam 2009
- Dome JS. Identification and management of high risk Wilms tumors.
(promotores R Pieters, M Coppes), Rotterdam 2009
- Van Beek RD. Endocrine effects of the treatment for acute lymphoblastic leukemia and Hodgkin's Lymphoma in childhood.
(promotor R Pieters, co-promotores MM van den Heuvel-Eibrink, SMPF de Muinck Keizer-Schrama), Rotterdam 2010
- Balgobind B. Unraveling MLL-rearranged pediatric acute myeloid leukemia.
(promotor R Pieters, co-promoter MM van den Heuvel-Eibrink, CM Zwaan) Rotterdam 2011
- Schotte D. MicroRNAs in pediatric acute lymphoblastic leukemia: small players with huge potential.
(promotor R Pieters, co-promotores ML den Boer) Rotterdam 2011
- Hollink I. Molecular genetic insights in cytogenetically normal pediatric acute myeloid leukemia.
(promotor R Pieters, co-promotores MM van den Heuvel-Eibrink, CM Zwaan) Rotterdam 2011
- Homminga I. Gene-expression profiles and oncogenes in pediatric T-cell acute lymphoblastic leukemia.
(promotor R Pieters, co-promotores JPP Meijerink) Rotterdam 2011
- Duijkers FAM. From epigenetic to Genetics in Neuroblastoma.
(promotor R Pieters, co-promotores MM van Noesel, JPP Meijerink) Rotterdam 2012
- Stumpel DJPM. Epigenetics in MLL-rearranged Infant Acute Lymphoblastic Leukemia.
(promotor R Pieters, co-promotor R Stam) Rotterdam 2012
- Van Waas M. Metabolic syndrome in childhood cancer survivors.
(promotor R Pieters, co-promotores MM van den Heuvel-Eibrink, SJCMM Neggers) Rotterdam 2012
- De Vries ACH. Molecular determinants of juvenile myelomonocytic leukemia and childhood MDS.
(promotor R Pieters, co-promotor MM van den Heuvel-Eibrink, CM Zwaan) Rotterdam 2012
- Coenen EA. The molecular heterogeneity of *MLL*-rearranged pediatric AML.
(promotor R Pieters, co-promotor MM van den Heuvel-Eibrink, CM Zwaan) Rotterdam 2013
- Te Winkel ML. Osteogenic toxicity in childhood acute lymphoblastic leukemia.
(promotor R Pieters, co-promotor MM van den Heuvel-Eibrink) Rotterdam 2013
- Segers H. Wilms tumors: genotypes and phenotypes.
(promotor R Pieters, co-promotor MM van den Heuvel-Eibrink) Rotterdam 2013
- Blink M. Clinical relevance of genetic alterations in acute myeloid leukemia in children with Down syndrome.
(promotor: R Pieters, co-promotores CM Zwaan, MM van den Heuvel-Eibrink) Rotterdam 2013
- Akbari Moqadam F. MicroRNAs in pediatric acute lymphoblastic leukemia: Functions and targets.
(promotor: R Pieters, co-promotor ML den Boer) Rotterdam 2014
- Ariës IMAA. Unraveling prednisolone resistance in pediatric acute lymphoblastic leukemia: towards personalized targeted therapy.
(promotor: R Pieters, co-promotor ML den Boer) Rotterdam 2014
- Spijkers-Hagelstein JAP. Unraveling glucocorticoid resistance in *MLL*-rearranged infant acute lymphoblastic leukemia.
(promotor: R Pieters, co-promotor RW Stam) Rotterdam 2014

- Van Dorp W. Determinants of gonadal function after childhood cancer.
(promotor: JSE Laven, R Pieters, co-promotor MM van den Heuvel-Eibrink) Rotterdam 2014
- Aalbers AM. Bone marrow failure syndromes and refractory cytopenia of childhood.
(promotor: R Pieters, co-promotor MM van den Heuvel-Eibrink, VHJ van der Velden)
Rotterdam 2014
- Tong WH. Efficacy and toxicity of asparaginases during prospective drug monitoring in patients with childhood acute lymphoblastic leukemia
(promotor: R Pieters, co-promotor IM van der Sluis) Rotterdam 2014
- Van der Veer A. B-cell precursor abnormalities in childhood acute lymphoblastic leukemia.
(promotor R Pieters, co-promotor ML den Boer) Rotterdam 2014
- Buitenkamp TD. Clinical relevance of genetic alterations in acute lymphoblastic leukemia in children with Down Syndrome.
(promotor R Pieters, co-promotor CM Zwaan, MM van den Heuvel-Eibrink) Rotterdam 2014
- Zuurbier L. Relevance of signal transduction pathway mutations in pediatric T-ALL.
(promotor: R Pieters, co-promotor JPP Meijerink) Rotterdam 2014
- Katsman-Kuipers JE. Altered gene & MiRNA regulation in pediatric acute myeloid leukemia.
(promotor: R Pieters, co-promotor MM van den Heuvel-Eibrink, CM Zwaan) Rotterdam 2015
- Van der Linden MH. Molecular and clinical dissection of infant acute lymphoblastic leukemia.
(promotor: R Pieters, co-promotor RW Stam) Rotterdam 2016
- Warris LT. Restore the balance: side effects of dexamethasone in children with acute lymphoblastic leukemia.
(promotor: R Pieters, MM van den Heuvel-Eibrink, co-promotor ELT van den Akker).
Rotterdam 2016
- Mendes RD. Unravelling pathobiological molecular mechanisms of T-cell acute lymphoblastic leukemia.
(promotor R Pieters, co-promotor JPP Meijerink) Rotterdam 2016
- Den Hoed MAH. The flip side of therapy: Body composition and bone density during and after childhood cancer therapy.
(promotor: R Pieters, MM van den Heuvel-Eibrink) Utrecht 2017
- Gooskens SLM. Clear cell sarcoma of the kidney.
(promotor: R Pieters, MM van den Heuvel-Eibrink) Utrecht 2017
- Van der Geest IMM. Experiences of parents and physicians with palliative care for pediatric cancer patients.
(promotor: R Pieters, MM van den Heuvel-Eibrink) Utrecht 2017
- Polak R. Molecular drivers of pediatric acute lymphoblastic leukemia.
(promotor: ML den Boer, R Pieters) Rotterdam 2017
- Jerchel IS. Signaling pathways as therapeutic targets.
(promotor: ML den Boer, R Pieters) Rotterdam 2018
- Kerstjens MJB. Identification of novel therapeutic strategies against MLL-rearranged acute lymphoblastic leukemia in infants.
(promotor: R Pieters, co-promotor RW Stam) Rotterdam 2019
- Driessen EMC. Determinants of clinical outcome in MLL-rearranged infant acute lymphoblastic leukemia.
(promotor: R Pieters, co-promotor RW Stam) Rotterdam 2019
- Oosterom N. (Epi)genetic and biochemical determinants of methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.
(promotor: R Pieters, MM van den Heuvel-Eibrink) Utrecht 2019
- Kloos RQH. Individualized asparaginase therapy for children with acute lymphoblastic Leukemia.
(promotor: R Pieters, co-promotor IM vd Sluis) Rotterdam 2020
- Reedijk AMJ. Progress against childhood and young adolescent cancer in the Netherlands since 1990.
(promotor R Pieters, LCM Kremer, JWW Coebergh) Utrecht 2020

- Van der Zwet JCG. Aberrant IL7R signaling: the paths towards steroid resistance in pediatric T-cell acute lymphoblastic leukemia.
(promotor: R Pieters, co-promotor JPP Meijerink) Utrecht 2022
- Cordo V. On the road towards targeted treatments for T cell acute lymphoblastic leukemia: a phosphoproteomic journey.
(promotores: R Pieters, C Jiminez, co-promotor JPP Meijerink) Utrecht 2023
- Schneider P. Towards unraveling the puzzle of KMT2A-rearranged infant acute lymphoblastic leukemia.
(promotor: R Pieters, co-promotor RW Stam) Utrecht 2024

TEACHING

- Medical students Amsterdam (1991-1998), Rotterdam (1999-2014) and Utrecht (2014-present)
- Residents pediatric department.
- Pediatric Nurses
- Dutch Association for Oncology Nursing - course pediatric oncology, 1996-present
- School for Pediatric Oncology Nursing
- Research training medical students and biology students
- Invited lectures at international and national meetings
- Postgraduate Course on Controversies and Recent Advances in Medical Oncology 1993
- European Society for Oncology/ International Society of Pediatric Oncology/American School of pediatric Oncology (ESO/SIOP/ASPO), yearly Postgraduate Course on Translational Research in Pediatric Oncology, 1999-present
- Educational courses for pediatric oncologists, SIOP
- Postgraduate Education for pediatricians, Amsterdam (1997-1999) and Rotterdam (1999-2014)
- Junior Med School 2008-2010
- Minor committee ErasmusMC 2008-2010
- Minor Pediatric Oncology 2010-2013
- Basiscursus Kinderoncologie voor niet-professionals 2015 - 2018
- Educational courses for pediatric oncology nurses, Utrecht, 2015- present
- Child Health Week, Utrecht, 2017 - present
- TULIPS, Utrecht 2017 - present
- Master Course Pediatric Oncology, Utrecht 2017 - present
- Dutch Society for Oncology, Ellecom, 2005 – present
- Expert Session Acute Lymphoblastic Leukemia, 2018 – present
- Preceptorship ALL 2021 – present
- CAR-T symposium 2019 - present
- Global Leukemia Academy 2020 – present
- Meet the Professor 2017 – present
- Summer Course Pediatric Oncology 2021 – present
- Doctors meets Director program 2020 – present
- MBA Nijenrode, Module Marketing en innovatie in de private sector, 2021
- Master Course Module Hemato-Oncology 2021 - present